

CSR Activities

CSR Management

In this section, we explain Daiichi Sankyo's corporate social responsibility (CSR) activities, which are integrated into its business activities and based on the DAIICHI SANKYO Group Corporate Conduct Charter (see below). Specifically, we have identified CSR issues that need addressing as the Group for social and environmental issues related to sustainability. Of these, we have extracted material CSR issues as "materiality*" based on their importance, and categorized them into six priority areas on which to act.

The Company has established and implemented a system to promote CSR management to resolve these CSR issues. We also communicate with our various stakeholders, taking their evaluations of the Group to heart and reflecting these evaluations in CSR activities.

* CSR issues deemed important from the viewpoint of an organization's effects on the economy/environment/society and effects toward the organization's mid- to long-term values

The Principles of Our Corporate Activities to Fulfill Our Mission

DAIICHI SANKYO Group Corporate Conduct Charter

The DAIICHI SANKYO Group fulfills its mission to "To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs." We comply with laws, regulations and rules regarding global corporate activities, and act with the highest ethical standards and a good social conscience appropriate for a company engaged in a business that affects human lives based on the following principles. We fulfill our CSR by actively responding to an ever-changing society and enacting improvements for corporate value.

- Article 1** We diligently address medical needs by providing beneficial, safe, and reliable pharmaceuticals and services.
- Article 2** We conduct business in an ethical, fair and competitive manner, and maintain a healthy and professional relationship with our stakeholders, which include medical professionals and governments.
- Article 3** We actively communicate with our stakeholders by disclosing corporate information in a timely and appropriate manner in accordance with the principles of corporate accountability. We take appropriate measures to manage and protect personal and customer information and the confidential information of our and other companies.
- Article 4** The globalization of business activities requires that we operate by being compliant with the laws of each country and region, and by being respectful to all international norms including human rights, various cultures and customs. As a result, we contribute to the development of the local economy and society.
- Article 5** We respect diversity in the personal values, qualities and individuality of our employees, and ensure a safe and working environment that does not tolerate inappropriate treatment such as discrimination or harassment. We provide employees with the opportunity to develop their skills and abilities for the mutual development of the employee and the corporation.
- Article 6** We responsibly manage the environmental impact of our operations as environmental issues are common challenges for mankind and such concerns are integral to our corporate activities and our very survival.
- Article 7** We actively engage in community activities and philanthropic programs focused on social causes.
- Article 8** We do not support or conduct our business with antisocial forces, prohibited entities or groups that may threaten the order or safety of civil society.
- Article 9** Executives of the DAIICHI SANKYO Group actively build and maintain effective systems to implement this Charter, ensure it is understood by all Group companies, and make this Charter known to our business partners.
- Article 10** If the Charter is violated, executives of DAIICHI SANKYO Group Companies ensure that there is a commitment to determine the cause of infringement, take corrective action as necessary and make efforts to prevent similar violations in the future. Executives are accountable for promptly making required disclosures and upon discerning responsibility regarding the infringement, impose appropriate disciplinary action, including upon Executives themselves.

The Group conducts activities to contribute to "Goal 3: Ensure healthy lives and promote wellbeing for all at all ages" of the Sustainable Development Goals (SDGs), particularly as a measure towards ever-changing sustainability issues. The SDGs are a set of goals for 2030 to address the key issues facing the world, and have been adopted by the member states of the United Nations. Seventeen goals to be accomplished by 2030 have 169 targets.

The Group's initiatives with regard to the 17 SDGs have been compiled into a list of the Daiichi Sankyo Group's initiatives related to the SDGs.



A list of the Daiichi Sankyo Group's initiatives related to the SDGs is available on the corporate website.
https://www.daiichisankyo.com/about_us/responsibility/csr/gc/index.html



SUSTAINABLE DEVELOPMENT GOALS



The Daiichi Sankyo Group's CSR Activities

CSR Activities Based on the DAIICHI SANKYO Group Corporate Conduct Charter

Based on the DAIICHI SANKYO Group Corporate Conduct Charter, we are conducting CSR activities as part of all of our corporate activities. The DAIICHI SANKYO Group Corporate Conduct Charter defines principles to be practiced in all of the Company's activities in order to fulfill its corporate mission. Taking each of these principles seriously and complying with legal regulations and rules, we act with the highest ethical standards and good social conscience appropriate for a company engaged in a business that affects human lives. Through this commitment, we strive to meet the diverse requirements and expectations of society to improve corporate value and thereby fulfill our CSR.

Identifying materiality in CSR activities and classifying their priority areas

Our CSR activities are based on responsible actions expected from pharmaceutical companies and global CSR initiatives such as the United Nations Global Compact (UNGC) from the perspectives of "diverse requirements and expectations of society" and "the relationship to our medium-to-long-term business." The materiality has been identified based on these CSR issues and categorized per activity area.

(See pages 76 to 77 "CSR 6 priority areas for activities, 36 items identified as materiality and examples of initiatives")

Step 1 Recognizing CSR issues and identifying materiality

We have reviewed the information on CSR issues that pharmaceutical companies generally need to address by referencing the global initiatives (Ten Principles of the UNGC^{*1}, ISO 26000^{*2}, etc.) and the evaluation criteria of ESG indices (Dow Jones Sustainability Indices, FTSE4Good Index Series, Access to Medicine Index, etc.) as well as the policies and visions of pharmaceutical company organizations (International Federation of Pharmaceutical Manufacturers & Associations, Japan Pharmaceutical Manufacturers Association, etc.) and then identified 36 items as materiality.

Step 2 Classifying priority areas for activities related to materiality

The 36 CSR issues identified as materiality were further organized and classified into six priority areas for activities (Promoting compliance management, Mutual growth of employees and the Company, Enhancement of communication with stakeholders, Promoting environmental management, Improving access to healthcare, and Social contribution activities).

*1 A voluntary initiative in which companies and organizations demonstrate leadership and act as upstanding members of society by participating in the creation of global frameworks aimed at realizing sustainable growth

*2 An international guidance standard aimed at helping companies and other organizations assess and address the social responsibilities relevant to their business

CSR 6 priority areas for activities, 36 items identified as materiality and examples of initiatives

Please refer to the Daiichi Sankyo website for initiatives with no page number.

Priority areas for activities	Materiality (36 items)	Examples of Initiatives	Page
Promoting Compliance Management	Observe Group-wide codes of conduct	Continued operation of the compliance system	80
		Implementation of a Compliance Awareness Survey	80
		Implementation of a Global Marketing Code of Conduct	
		Dissemination of the ICP	
		Compliance training and educational activities	
	Anti-corruption	Establishment of Global Policies Related to Preventing Bribery and Corruption	81
	Ensure transparency of corporate activities	Measures for ensuring the transparency of corporate activities	
	Conduct clinical trials in accordance with ICH-GCP	GCP and other development-related training	
	Product quality and safety assurance	Product Safety-related training (GVP training) Implementation of quality audit for raw materials suppliers	
	Ethical marketing practices	MR accreditation test results (Japan) Ethical MR promotional activity	
Promoting Environmental Management	Consider bioethics and genetic resources	R&D ethics Fair utilization of genetic resources	
	Sustainable procurement	Promotion of compliance in procurement Implementation of CSR Self-Assessment Surveys Establishment of Sustainable Procurement Guideline	81 81
	Report on critical recalls	Product recall information	
	Report on breach of laws and legal cases	Business risks	
Improving Access to Healthcare	Respect human rights in business activities	Training related to the UNGC	
	Tax strategy	Our Approach to Tax	
	Report on critical recalls	Product recall information	

Please refer to the Daiichi Sankyo website for initiatives with no page number.

Priority areas for activities	Materiality (36 items)	Examples of Initiatives	Page	
Mutual Growth of Employees and the Company	Develop human resources	Group talent management Recruitment and human resources development policies Development of entry- and mid-level employees Cultivation of line managers (organization heads)	82	
	Acquire and retain talented individuals	Daiichi Sankyo Human Resources Management Philosophy Benefit plan		
	Promote diversity	Acquisition of the Highest Grade of Eruboshi Certification based on the Act on Promotion of Women's Participation and Advancement in the Workplace Promotion of Diversity and Inclusion Endorsement of The Women's Empowerment Principles (WEPs) Participation in IkuBoss Alliance Support for the career development and work styles of diverse employees Support for the career development of women employees (Japan) Initiatives based on action plan for empowering women Acquisition of "Kurumin" next-generation authorization mark certification Promotion of the employment of individuals with disabilities Systems and measures to support diverse work styles (Japan)	83	
	Communication between labor and management	Communication with labor unions		
	Respect human rights in labor practices	Policy for respecting human rights Initiatives for promoting respect for human rights		
	Pay equal wages to men and women	Training related to the UNGC		
	Promote work-life balance	Promotion of the "Work-Life Cycle" (Japan)		
	Prevent occupational accidents	Promotion of occupational health and safety 2018 Certified Health and Productivity Management Organization Recognition Program (Large Enterprise Category)—White 500 Systems and initiatives for supporting occupational health and safety (Japan)	83 83	
	Enhancement of Communication with Stakeholders	Identify, respond to, and disclose material CSR issues	CSR management	76
		Improve customer satisfaction	Addressing inquiries from patients and healthcare professionals	84
Respond to complaints		Use of the Compliance Reporting System		
Stakeholder engagement		Stakeholder Dialogue	84	
		Aiming for Being a Trusted Medical Partner	85	
		Communication with healthcare professionals and patients	85	
External verification for CSR reports	External verification of environmental reports			
Promoting Environmental Management	Address climate change	Efforts for Saving Energy and Combatting Global Warming CO ₂ emissions reduction targets and performance CO ₂ emissions reduction initiatives	87	
	Manage chemical substances	Usage reduction and emission and transfer control of chemical substances		
	Control water usage volumes	Management of water risks Appropriate use of water resources		
	Manage waste	Auditing Environmental Management Waste reduction targets and performance Promotion of compliance for waste management	87	
	Preserve biodiversity	Biodiversity initiatives		
Social Contribution Activities	Receive ISO 14001 and other environmental management system certification	Optimization of the environmental management system	86	
	Address global health issues	Participation in Access Accelerated initiative	88	
		Participation in the GHIT Fund	89	
		Continued initiatives targeting rare diseases	89	
	Measures to combat counterfeit medicines	Mobile healthcare field clinic services in Tanzania	89	
		Cultivation of healthcare workers in China	90	
	Address cost burden	Technical cooperation related to manufacturing the combined measles-rubella vaccine (MR vaccine) Clinical trials to be conducted from a humanitarian viewpoint		
Health outcome contribution	Measures to combat counterfeit medicines			
Social Contribution Activities	Address cost burden	Patient Assistance Programs (United States)		
	Health outcome contribution	Disclosure of clinical trial information		
	Conduct social contribution activities suited to a pharmaceutical company	Support for cancer patients and their families	91	
		Reconstruction support following the Great East Japan Earthquake	91	
Support for disabled/seriously ill children and their families (United States)				
Activities that heighten awareness of atrial fibrillation (Spain)				
Activities that promote health in senior citizens (Taiwan)				
Advancement of medicine and pharmacology (scholarships, etc.)				
Social welfare (Table for Two, etc.)				
Environmental preservation activities (cleanup activities around operating sites, etc.)				
Youth development (science and pharmacology seminars for high school students, etc.)				

Promotion of CSR Activities

The Daiichi Sankyo Group is constructing a CSR management cycle based on the global management structure (see page 60) to promote CSR activities that are integrated into business operations.

Extracting CSR issues

Issues are extracted based on expectations and needs identified through various CSR initiatives stakeholder communications or results of the reviews by CSR/ESG evaluation organizations, and these are shared with related divisions and group companies.

Prioritizing issues

Issues that need to address are based on business strategies and requests from stakeholders, etc.


Appropriate responses to priority issues

Cooperation with related divisions and group companies to promote issues that should be prioritized.

Stakeholder communication

We conduct self-assessment through stakeholder communication such as reviews by CSR/ESG evaluation organizations and disclosure of responses regarding priority issues.

Progress on measures taken on issues is shared with senior management when necessary, and senior management makes decisions related to important issues. These activities are continuously implemented to improve CSR/ESG external evaluation.



Inclusion in ESG Indices in Reflection of External CSR/ESG Evaluations

To address sustainability issues, we pursue ongoing improvements to our corporate values by integrating our CSR activities with business activities. These efforts have been highly appreciated, resulting in the Group being as the first Japanese corporation selected for the "DJSI World Index" pharmaceutical sector in September 2017.

The first Japanese corporation to be listed for the pharmaceutical "World Index"



The DJSI is managed cooperatively by S&P Dow Jones Indices LLC of the United States and RobecoSAM AG of Switzerland. This ESG index evaluates the sustainability of a company and provides important criterion for investors to select investment targets. The Company has been included in the DJSI World Index for the first time and the DJSI Asia/Pacific for eight consecutive years.

Areas in which Daiichi Sankyo was rated the highest among pharmaceutical companies

Economic Dimension	<ul style="list-style-type: none"> Codes of Business Conduct Materiality
Environmental Dimension	<ul style="list-style-type: none"> Climate strategy
Social Dimension	<ul style="list-style-type: none"> Occupational Health and Safety Health Outcome Contribution Strategy to Improve Access to Drugs

In addition to this, we have also been selected for the "DJSI Asia/Pacific," "RobecoSAM Sustainability Award Silver Class 2018," "FTSE4Good," "FTSE Blossom Japan," "MS-SRI," "SNAM Sustainability Index," and the "MSCI Japan Empowering Women (WIN) Select Index."

The first Japanese company to be selected for the "Silver Class" in the pharmaceutical sector



The Company has been selected for the "Silver Class" of Swiss-based RobecoSAM Sustainability award in the pharmaceutical sector. The Silver Class distinction is given to the companies within the range of one to five percent of the industry's top-performing company's score. Daiichi Sankyo was recognized for the entire Environmental Dimension including Climate Strategy. As well, the Company was also recognized for its strong performance in the area of Codes of Business Conduct and Materiality in the Economic Dimension, Occupational Health and Safety, Health Outcome Contribution and Strategy to Improve Access to Drugs in the Social Dimension. There were two companies selected in the Gold Class for pharmaceuticals along with four Silver Class companies including Daiichi Sankyo, and two in the Bronze Class.

Selected consecutively for ten years



An index that reflects the performance of companies demonstrating strong environmental, society, and governance (ESG) practices, established by FTSE Russell, a global index provider and wholly-owned subsidiary of the London Stock Exchange Group plc. The FTSE4Good index series is used as a benchmark for investors to identify corporations that have overall good performance in ESG initiatives. The Company has been selected for ten consecutive years as a component of the FTSE4Good Global Index from 2009.

Selected consecutively for two years



An industry-neutral benchmark that reflects the performances of companies demonstrating strong environmental, society, and governance (ESG) practices in Japan, established by FTSE Russell, a global index provider and wholly-owned subsidiary of London Stock Exchange Group plc. The FTSE Blossom Japan Index is used for sustainable investments and widely applied in creating and assessing other financial products and funds. It has been newly selected by the Government Pension Investment Fund (GPIF) as an ESG Index. Through third-party screening, the Company has fulfilled the requirements to enter the FTSE Blossom Japan Index, and has been selected two years in a row for this index.

Selected consecutively for ten years



Morningstar Japan KK selects 150 companies each year from among Japanese listed companies. This index includes those companies that have been regarded as excellent from the perspectives of governance, environmental, social, and human resources development. The Company has been included in this index for ten consecutive years beginning with 2008.

Selected for the first time



The MSCI Japan Empowering Women (WIN) Select Index is one of three indexes selected by the Government Pension Investment Fund (GPIF) as an ESG Index in Japanese stock. It assesses gender diversity in corporations such as the female ratio among new recruits, employees, average work years and the ratio of female executives, and comprises corporations that excel in these factors. In June 2018, the Company was included in this index for the first time.

THE INCLUSION OF DAIICHI SANKYO CO.,LTD. IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF DAIICHI SANKYO CO.,LTD. BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES.

(As of the end of June 2018)

Selected consecutively for three years



The SNAM Sustainability Index is an SRI fund managed by Sompo Japan Nipponkoa Asset Management Co., Ltd., aimed at pension funds and institutional investors that invest in a wide range of companies highly rated in terms of ESG factors (environment, society, governance). The Company has been included in this index for three consecutive years.

Initiatives toward materiality

In April 2018, we established a global "Access to Healthcare Policy" that addresses our goal to unite as a company towards global health. The policy summarizes research and development, pharmaceutical technologies, manufacturing, sales and marketing, quality & safety management.

We also recognize the importance of promoting CSR in the supply chain, and revised the "Global Procurement

Policy," the highest-level policy for procurement, in October 2017, along with revising the "Sustainable Procurement Guideline." The Daiichi Sankyo Group takes appropriate measures toward various sustainability issues including social/environmental issues such as human rights, gender equality, prevention of corruption, environmental conservation and global health.

Promoting Compliance Management

No matter how successful or strongly performing a company may be, it will be unable to continue corporate activities within society if it does not practice good compliance. Therefore, as a global pharmaceutical company, the Daiichi Sankyo Group practices management founded on compliance.

Basic Policy

At the Daiichi Sankyo Group, we define integrity as one of our Core Values. We have therefore positioned compliance as the standard we use in making decisions and value judgments. In conducting our global business operations, we remain compliant with all relevant laws and regulations and conduct compliance management with a strong focus on ensuring the highest level of ethics and social consciousness, which is essential for a life science-oriented company.

To guide us in these efforts, we have established the Daiichi Sankyo Group Corporate Conduct Charter (Charter) and the Daiichi Sankyo Group Individual Conduct Principles (ICP), which are applied throughout our operations. Based on the essence of the Charter and the ICP, the Company and other Group companies have developed compliance conduct standards appropriate to their respective regions and social requirements. Awareness regarding these standards is being entrenched among all executive officers and employees.

CSR Highlights	
Targets Dissemination of global compliance policies including the Daiichi Sankyo Group Individual Conduct Principles	Fiscal 2017 Accomplishments <ul style="list-style-type: none"> ▶ Conducted a compliance awareness survey ▶ Conducted CSR self-assessment survey on CSR procurement ▶ Established and rolled out Global Anti-Bribery & Anti-Corruption Policy

How we address CSR issues

Materiality Observe Group-Wide Codes of Conduct

Continued Operation of Compliance System

In Japan, the head of the Corporate Affairs Division serves as the compliance officer, a position that entails managing our entire compliance program, which includes the Daiichi Sankyo Code of Conduct for Compliance and related rules and annual objectives. The compliance officer also serves as the chairperson of the Company's Corporate Ethics Committee in Japan. This committee is a deliberation and decision-making body for compliance that meets twice per year, in principle, and is made up of 13 members including 12 internal representatives and an appointed external attorney, who ensures that the committee operates in a transparent and reliable manner. Full-time Members of the Audit and Supervisory Board will also participate as observers. In addition, a compliance officer, etc. is appointed at each Group company in Japan and overseas to promote and oversee compliance programs at their respective companies.

Furthermore, in order to ensure the effectiveness of Daiichi Sankyo Group's global compliance system, we established the Global Compliance Advisory Committee as an advisory organ to the Corporate Ethics Committee. Full-time members of the committee include compliance officers from subsidiaries in Europe and the United States, and the committee is responsible for examining the global policies and annual targets of the Group. Deliberations made at the Corporate Ethics Committee and the Global Compliance Advisory Committee are reported to the CEO, COO and the Board of Directors as Fiscal Year Promoting Activities on Compliance.

Implementation of a Compliance Awareness Survey

A compliance awareness survey was conducted in approximately 9,000 corporate and domestic Group executives and employees (including temporary and contract staff). The response ratio was 96.7% for the entire Group in fiscal 2017. We were able to ascertain the Group's strengths and issues through this survey by analyzing factors such as comprehension levels of the

Group's mission and compliance-related codes, compliance implementation, and development of in-house systems. The results of this survey were reported to the Corporate Ethics Committee, CEO and COO, and also analysis results for each organization were delivered as feedback to each unit head, Group President and persons in charge of promoting compliance in Japan in order to utilize as basic data for activities promoting compliance in the next fiscal year.

Materiality CSR Procurement

Promotion of Compliance in Procurement

In October 2017, our Group revised the Global Procurement Policy, which is the highest prioritized policy for procurement. It clearly states that we will formulate a Supplier Code of Conduct including six items (1. Ethics 2. Labor 3. Health and safety 4. Environment 5. Ensuring optimal quality, cost, and stable supply 6. Management systems) for all Group companies, including overseas subsidiaries, and bolster CSR procurement throughout the entire Group.

Implementation of CSR Self-Assessment Surveys

The CSR self-assessment surveys previously conducted were positioned as an initiative for the entire Group including overseas subsidiaries. Furthermore, we have decided to take a broader approach with this, and newly apply it to business partners (suppliers) of indirect materials as well as raw materials. For fiscal 2017, we conducted CSR self-assessment surveys for the top 100 companies for both direct and indirect materials.


Moreover, Daiichi Sankyo and domestic Group companies have also started conducting surveys toward secondary suppliers of important direct materials.

Materiality Thorough Prevention of Corruption

Establishment of Global Anti-Bribery & Anti-Corruption Policy

The laws and regulations against bribery and other forms of corruption in countries around the world are growing stricter with each coming year. Thus, it is becoming increasingly important for companies developing their operations on a global scale to implement initiatives for preventing bribery and other forms of corruption. Our Group clearly states preventing bribery and corruption as a basic principle per field in the Daiichi Sankyo Group Individual Conduct Principles. However, to make even greater strides toward these policies, the Daiichi Sankyo Group global anti-bribery and anti-corruption policy was newly established in October 2017, and includes details such as prohibiting cash payment to government officials and healthcare professionals.

We reviewed corporate policies and procedures and related operations of the Company and other Group companies, and conducted training programs for anti-bribery and anti-corruption. Our Group will continue to conduct training programs for anti-bribery and anti-corruption regularly, and bolster our corporate structure. We will especially take measures against bribery and other unwanted activities in business in high-risk countries. (See "Voice" below)

 The Company updates its corporate website with information on other initiatives.
https://www.daiichisankyo.com/about_us/responsibility/csr/business/fair/index.html

VOICE

Aiming to Develop a High Awareness of Compliance

The Compliance Group of the Legal Affairs Department is responsible for promoting compliance on a Group-wide basis. Group companies that posed a high risk of bribery and other corruption were checked when implementing the Daiichi Sankyo Group Global anti-bribery and anti-corruption policy established in October 2017. Gifts and cash payment to healthcare professionals were reviewed to see whether there is any dishonest practices, confirming any dishonest practices, and instruction was given when applicable. We have also distributed anti-bribery and anti-corruption training material to overseas subsidiaries to support raising comprehension and awareness among employees. We will contribute to foster higher levels of compliance awareness through these activities.



Naoki Hatakeyama

Senior Director, Compliance Group, Legal Affairs Department, Corporate Affairs Division, Daiichi Sankyo Co., Ltd.

Mutual Growth of Employees and the Company

The Daiichi Sankyo Group considers its people to be its most important asset, and pursues long-term growth by practicing innovation, integrity and accountability as described in its Core Values.

Basic Policy

At Daiichi Sankyo, we believe that employees, through their embodiment of the Daiichi Sankyo Group's Core Values and their diligent daily efforts to carry out our Commitments in and outside the Company, will be a strong driving force behind realizing our vision and fulfilling our mission.

The Daiichi Sankyo Human Resources Management Philosophy was designed to support the development, empowerment, and fair treatment of employees that, irrespective of their location in the world, share in the principles of innovation, integrity and accountability. At the same time, we expect employees to uphold the ethics and

standards we have defined and to work toward the realization of our corporate vision.

To improve the speed and quality of the Daiichi Sankyo Group's global operations, it is essential that businesses in different regions coordinate and collaborate closely with one another. We are further expanding our global business by providing rotational opportunities for our employees among our locations in different countries and regions, thus enabling employees to experience different cultures and ways of thinking and creating an environment in which diversity is respected.

CSR Highlights	
<p style="text-align: center;">Targets</p> <p>Human resources development to realize value creation and secure competitive advantage through our Core Values of innovation, integrity, accountability, and respect for diversity</p>	<p style="text-align: center;">Fiscal 2017 Accomplishments</p> <ul style="list-style-type: none"> ▶ Promoted Group talent management ▶ Obtained the highest grade of Eruboshi certification for promoting women's participation and advancement in the workplace (in 2018) ▶ Selected for the 2018 Certified Health and Productivity Management Organization —White 500 (Fiscal 2018)

How we address CSR issues

Materiality Human Resources Development

Group Talent Management

Daiichi Sankyo promotes talent management with primary focus on leadership development, with the aim of continuously producing quality leaders in future generations.

• Shared Global Initiatives

We have identified global key positions that are vital for realizing our Vision/mid-term business plan (34 positions as of April 2018). By visualizing successor candidates and their development goals, Daiichi Sankyo effectively promotes leadership development measures tailored to employees' individual challenges, and offers training programs, opportunities, and positions that allow for their further growth. We have also been actively carrying out international assignment and overseas study programs to

allow future leaders to expand their horizons and comprehend global business. As of April 2018, around 100 individuals participate in these initiatives.

• Regional Initiatives

We have been organizing structures to develop future leaders in Japan, the U.S., Europe and ASCA. For example, in the ASCA region, we select candidates for next generation leaders from each country, and hold joint training sessions at our Headquarters in Japan. Participants boost/develop their leadership capabilities while debating/exchanging opinions on expansion and growth in emerging markets.

To ensure these initiatives are carried out, HR representatives from Japan, the U.S., Europe and ASCA region meet regularly to exchange information on the progress of shared global initiatives as well as regional initiatives.

Materiality Diversity

Acquisition of the Highest Level of Eruboshi Certification for Promoting Women's Participation and Advancement in the Workplace

In May 2018, Daiichi Sankyo obtained the highest level (Grade 3) of "Eruboshi" certification for promoting women's participation and advancement in the workplace. Under the Act on Promotion of Women's Participation and Advancement in the Workplace which went into effect in April 2016, the Japanese Minister of Health, Labour and Welfare grants "Eruboshi" certifications to companies with outstanding efforts in implementing initiatives to empower the women in its workplace. We have provided opportunities for development based on each individual's potential and aptitude for a job, and will continue to improve the environment that helps realize growth in every individual through work. Daiichi Sankyo and its Japanese affiliates have childcare support systems that help employees to make a smooth return to work from childcare leave as well as to assist balance work with childcare upon return. At the same time, we are actively building a workplace environment in which the systems are easily used without hesitation. As a result, we have obtained the "Kurumin" next-generation authorization mark certification from the Japanese Ministry of Health, Labour and Welfare.



• Mid-term policy of occupational health and safety management

1. Promote employee health
2. Bolster mental health care
3. Execute measures toward safety management and comfortable workplace/working environment
4. Enhance occupational health and safety system

Based on the Human Resources Management Philosophy, which gives maximum consideration on employees' mental and physical health, we strive to maintain and improve employees' health in collaboration with the Daiichi Sankyo Group Health Insurance Association and labor union.

2018 Certified Health and Productivity Management Organization Recognition Program (Large Enterprise Category)—White 500

In fiscal 2017, we established a corporate structure with a CHO (Chief Health Officer) as the head toward maintaining and improving employees' health. A Declaration of Health has also been issued by the CHO. At the moment, Daiichi Sankyo is working with the Health Insurance Association and labor union to enhance the environment where employees can actively maintain/improve their health by accurately understanding their own physical condition. We have set performance indicators and goals to reinforce health guidance and employee awareness. (See "Voice" below)

In February 2018, Daiichi Sankyo has been selected for the 2018 Certified Health and Productivity Management Organization (White 500) by the Japanese Ministry of Economy, Trade and Industry. We received this recognition based on our continuous efforts to date, and on enhanced initiatives including the appointment of a CHO.



The Company updates its corporate website with information on other initiatives.
https://www.daiichisankyo.com/about_us/responsibility/csr/business/human/index.html

Materiality Prevention of Occupational Accidents

Promotion of Occupational Health and Safety

The Daiichi Sankyo Group determines and implements measures for each fiscal year based on the mid-term policy of occupational health and safety management which the senior management and trade union have agreed.

VOICE

Establishing Performance Indicators Related to Employee Health Maintenance and Improvement

Daiichi Sankyo has established an environment in which employees can proactively maintain their health. We believe this will promote behavioral changes that will result in preventing health problems in the future.

We promote the PDCA based on performance indicators and goals related to maintenance and improvement of employees' health to encourage their behavioral changes.

To meet such goals, for fiscal 2018, we will develop and execute various measures to improve employee's health awareness and literacy, through discussion and collaboration with the labor union.



Takashi Munesue

Employee Relations Group, Human Resources Department, Corporate Affairs Division
 Daiichi Sankyo Co., Ltd.

Enhancement of Communication with Stakeholders

Responding to the social demands and expectations for the Daiichi Sankyo Group is crucial to the sustainability of corporate activities.

We therefore communicate with our various stakeholders to foster mutual understanding, while pursuing cooperation.

Basic Policy

We believe that in order to achieve sustainable growth and the medium-to long-term growth of corporate value, it is important to communicate with various stakeholders such as patients, their families, healthcare professionals, shareholders, investors, employees, business partners,

and communities. By communicating with these various stakeholders, we are able to learn about their demands and expectations for us. Moreover, by explaining the Group's initiatives, we will foster mutual understanding and facilitate cooperation for realizing a sustainable society.

CSR Highlights	
Targets Effective disclosure of CSR and ESG information and improvement in external evaluation	Fiscal 2017 Accomplishments <ul style="list-style-type: none"> ▶ Maintained the top ranking for six consecutive years in overall assessments of MR activities ▶ Swiftly and accurately responded to inquiries by introducing a call center support system using AI (artificial intelligence) ▶ Implemented the Management Caravan program, allowing for direct communication with employees both in Japan and overseas.

How we address CSR issues

Materiality Improve customer satisfaction

Aiming for being a trusted medical partner

Medical representatives (MRs) play a particularly important role in providing, gathering, and disseminating information to healthcare professionals including doctors and pharmacists. Information that healthcare professionals need differs greatly depending on the circumstances of the patient examined as well as the position and role of the healthcare professional. For example, they may be a family doctor, a specialist, a hospital pharmacist or at a dispensing pharmacy. Based on Daiichi Sankyo's Bright Days Together (BRIDGE) concept, we hope to form a bridge to a brighter future for patients, their families, and healthcare professionals by responding appropriately to a wide range of diverse and constantly changing information requirements, and by striving to provide assistance. In addition, we aim to be seen as a trusted medical partner by all people involved in healthcare.

We also pursue continual improvements in the activities of MRs in Japan by utilizing surveys conducted on healthcare professionals by third-party research firms. In fiscal 2017, Daiichi Sankyo was ranked No. 1 in Japan in an overall assessment of MR activities in both the entire market and the hospital and private-practice market

categories. We have maintained the top ranking for six consecutive years in the entire market and hospital categories, beginning with fiscal 2012.

Response to Inquiries from Patients and Healthcare Professionals

Our Medical Information Center strives to serve patients and healthcare professionals with the utmost respect and empathy while delivering accurate information. The Center puts into practice its four commitments: providing highly specialized information, giving consistent and high-quality responses, addressing customers cordially, and utilizing customer feedback.

In fiscal 2017, we made the decision to introduce a call center support system using AI (artificial intelligence), and took the lead over other companies from April 2018 in adopting this system for inquiry response operations aimed at Q&A for all products. This system recognizes the intent and meaning of inquiries, and finds closely related Q&A data in an instant so as to deliver an optimal answer for the individual making the inquiry. We have previously launched initiatives to improve response speed including the preparation of new Q&As and the refinement of product knowledge. We introduced AI with the goal of delivering information even more swiftly as an effective enhancement that can bring immediate results. (See "Voice" on page 85.)

Materiality Communication with Stakeholders

Communication with Shareholders and Investors

The Company discloses information according to its IR information disclosure policy, which complies fully with disclosure regulations. The policy calls for engaging in the timely and proactive disclosure of information for shareholders, investors, and other market players based on the principles of transparency, impartiality, and continuity.

In fiscal 2017, our IR activities included delivering the Convocation Notice of Ordinary General Meeting of Shareholders (in both Japanese and English) three weeks in advance as well as disclosing information four weeks in advance on the Internet. This was to ensure sufficient time for shareholders in Japan and overseas to consider before exercising their right to vote. In addition, we held a briefing session for shareholders in Nagoya to provide a place for communication with shareholders.

We also held quarterly financial results presentations and conference calls by the management, an R&D Day as well as the Daiichi Sankyo Seminar, which was hosted by internal specialists for institutional investors. Some of our newly launched initiatives include organizing seminars for institutional investors held immediately after R&D product presentations made at academic conferences, and holding similar seminars for securities companies upon request. As part of the regular activities for gathering IR information, we participated in conferences held by securities companies and visited and held teleconferences with institutional investors. These activities took place on approximately 350 occasions both in and outside Japan. With regard to ESG, we had conversations with experts and investors on six occasions, and held nine shareholder relations (SR) consultations for individuals dealing with voting.


In addition, we issued a twice-monthly IR e-mail magazine to investors, featuring recent topics related to the Group.

Eight briefings for individual investors were held at locations across Japan with roughly 900 participants in total.

Communication with Employees

Daiichi Sankyo takes steps to ensure active internal communication with the aims of facilitating an understanding of management circumstances and fostering a corporate culture in which the organization and its employees act as one to pursue the Company's objectives.

In fiscal 2017, we implemented the Management Caravan program. This program involved the CEO and COO among other directors visiting 33 operating bases located across Japan as well as making visits to overseas Group companies in view of achieving the 2025 Vision and 5-year business plan.



The Management Caravan at Daiichi Sankyo Brazil

Communication with Local Communities

Located in the Nihonbashi district of Tokyo, which has historically been associated with medicine, the Daiichi Sankyo Kusuri Museum is used in various ways including company training, school trips, and industry research by job hunters.

This facility is entering its seventh year of operation in 2018, and a total of 100,000 people have visited over the years.

The Company updates its corporate website with information on other initiatives.
https://www.daiichisankyo.com/about_us/responsibility/csr/business/communication/index.html

VOICE

Aiming to Achieve Even Greater Satisfaction with Our AI Inquiry Response System

The Medical Information Center receives around 500 inquiries from healthcare professionals and patients every day. The Center endeavors to acquire knowledge related to Daiichi Sankyo's products and the diseases they treat so that it can provide swift and accurate responses to a wide range of inquiries. Our Medical Information Center has received high praise and trust in its responses to inquiries. The Center takes care in responding to inquiries courteously as a representative of the Company, and strives daily to make inquirers feel happy to have contacted Daiichi Sankyo. To further enhance the quality of the responses, we started running a call center support system using AI (artificial intelligence) in April 2018, enabling us to promptly deliver necessary and optimal information. Daiichi Sankyo aims to achieve even greater satisfaction with our AI inquiry response system going forward.



Rika Nagasaki

Medical Information Center Group I, Medical Information Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd.

Promoting Environmental Management

As the impact of various environmental factors increases, we will need to help realize a sustainable society if we are to continue our corporate activities.

Accordingly, we are promoting environmental management in order to reduce our environmental impact, manage environment risks and address climate change issues across the entirety of our business operations.

Basic Policy

Environmental issues such as global warming and extreme weather could be seen as very closely related to our lifestyles and work. We are practicing environmental management on a global scale in accordance with the DAIIICHI SANKYO Group Corporate Conduct Charter and the Basic Environmental Management Policy. We thereby aim to address such environmental issues through responsible corporate activities.

Basic Environmental Management Policy

Safeguarding the environment is the foundation of all Group operational management. We pursue environmental management that contributes to a sustainable society and enhances our good corporate citizenship.

CSR Highlights

Targets

Reducing environmental impact and risks, and addressing climate change (CO₂ emissions target for fiscal 2020: 5.6% reduction from fiscal 2015)

Fiscal 2017 Accomplishments

- ▶ Acquired ISO14001 multi-site certification
- ▶ Conducted environmental audits under the theme of environment-related laws
- ▶ CO₂ emissions: 228,557t (7.1% reduction from fiscal 2015)
- ▶ Ranked No.1 among pharmaceutical corporations in effective efforts to address climate and energy issues evaluated by WWF Japan (2018)

How we address CSR issues

Enhancing Environmental Management System

The head of the General Affairs Division of Daiichi Sankyo serves as the chief executive officer of environmental management and oversees environmental management on a Group basis, while the vice president of the CSR Department promotes environmental management as the environmental management officer. As a system for promoting environmental management, we have established an environmental management unit that takes business activities into consideration, and each environmental management unit establishes an environmental management site that considers regions and functions as necessary, and manages the goals. In addition, we have established an Environmental Management Committee chaired by the chief executive officer of environmental management. This committee discusses the formulation of environmental management policies and other important matters to report to the Board of Directors.

Optimizing the Environmental Management System

Operating sites that use large amounts of energy for manufacturing have acquired the certification of ISO14001, the international standard for the Environmental Management System (EMS). We acquired ISO14001 multi-site certification in January 2018. The certification covers CSR Department, all production sites in Japan and newly added Kitamoto site of Kitasato Daiichi Sankyo Vaccine. The objective of acquiring the certification is to strengthen governance of environmental management. Other operating sites have established and comply with the "Daiichi Sankyo Group Environmental Management System Standard Documents" to build an EMS according to the ISO14001 standards.

In our overseas Group, the Brazil Alphaville Plant has also acquired ISO14001 certification. We have started taking action towards acquiring ISO14001 certification for the Beijing and Shanghai Plants in China, and the Altkirch Plant in France for fiscal 2018.

The Daiichi Sankyo Group operates EMS to reduce environmental impacts and risks throughout all Group activities under "Optimization of the Environmental Management System." (See page 87, VOICE)

Auditing Environmental Management

The Group's auditing system for environmental management comprises three complementary approaches that are implemented in accordance with the situation at each operating site. These approaches include internal audits implemented by each operating site, evaluations by ISO audit organizations, and environmental audits performed by the environmental management team of CSR Department. Environmental audits of all operating sites by the CSR Department focus on compliance with environmental laws. For fiscal 2017, audits were conducted at the Daiichi Sankyo Headquarters, the Shinagawa/Kasai Research and Development Center, Daiichi Sankyo Healthcare and the Daiichi Sankyo (China) Beijing Plant and Shanghai Plant. The audits confirmed that good compliance was being practiced and that there were no concerns with the potential of leading to major environmental risks.



Environmental audit at the Beijing Plant

Materiality Initiatives for Climate Change

Efforts for Saving Energy and Combatting Global Warming

The Fourth Medium-Term Environmental Management Policy states that we should "Lower the environmental impact of all operations by conserving energy and resources, and by reducing greenhouse gas emissions and waste." Acting in accordance with this policy, we are working to use resources and energy more efficiently.

To facilitate responsible corporate activities that address climate change, we have set a CO₂ emission target for fiscal 2020, the final year of the 5-year business plan, of pursuing a 5.6% reduction from fiscal 2015 based on our long-term CO₂ emission target of reducing 27% for fiscal 2030 and the approach of the Science Based Targets (SBT) initiative,* which aims to help accomplish the goal of the Paris Agreement of keeping the average increase in global temperature below 2°C. This CO₂ emissions target places us at the second SBT-certified company in Japan, and Daiichi Sankyo will continue to cooperate with the Ministry of the Environment in SBT promotional activities.

We reached No.1 pharmaceutical company on Ranking of Japanese Corporations for Effective Efforts to Address Climate and Energy Issues rated by WWF in June 2018. Furthermore, we are taking actions against Climate Change such as participating in the "Japan Climate Initiative" that started in July of the same year.

During fiscal 2017, at the plant and laboratories in Japan, an "Energy-saving assessment" was conducted for the evaluations and improvement of energy use. Operating sites in Europe and Brazil have significantly reduced CO₂ emissions by using renewable energy. We are continuously introducing the renewable energy at the overseas operating sites.

CO₂ emissions for fiscal 2017 were 228,557t (7.1% reduction from fiscal 2015).

* An international initiative that encourages companies to set CO₂ reduction targets based on scientific evidence in order to help accomplish the goal of the Paris Agreement of keeping the average increase in global temperature below 2°C.

The Company updates its corporate website with information on other initiatives.
https://www.daiichisankyo.com/about_us/responsibility/csr/business/environment/index.html

VOICE

Fulfilling "Integrate EMS and Business Activities" for ISO14001

The Kitamoto site of Kitasato Daiichi Sankyo Vaccine acquired ISO14001 certification in January 2018. Upon acquiring certification, multiple briefing meetings were held to promote understanding of what it means, and EMS restructuring was carried out aiming to integrate business and CSR activities.

Specifically, we have set environmental targets to reduce waste and increase yield in the manufacturing and research divisions. We have also established the EMS that links the organizational goals of each division to the environmental improvements, such as by setting support and management as the environmental objectives in the staff division. As a result, we were able to realize the business activity goal of a stable vaccine supply and minimal product returns along with the EMS goal of reducing waste and saving resources, so we were able to fulfill the integration of business and environmental management with ISO14001. We will also promote business operations concerning biodiversity and the surrounding environment.



Tomohiro Azetsu

General Affairs Department, Kitasato Daiichi Sankyo Vaccine Co., Ltd.

Improving Access to Healthcare

Improving access to healthcare is an important mission as a pharmaceutical company. Unmet medical needs and access barriers to essential healthcare caused by social factors such as public health, education and income inequality are social issues against health and medical care. We are effectively utilizing internal and external resources to contribute to the resolution of these social issues.

Basic Policy

At the Daiichi Sankyo Group, our mission is "to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs." Seeking to accomplish this mission, the Daiichi Sankyo Group utilizes various internal capitals such as human capital, intellectual capital, financial capital, and social and relationship capital through partnerships and open innovation. With these resources, we are able to take advantage of the Company's strengths in terms of science and technology, its global organization and talent, and solid presence in Japan in order to advance our business activities, thereby contributing to the evolution of society.

Pharmaceutical companies face a multitude of challenges surrounding access to healthcare that must be addressed. These include unmet medical needs, access barriers to essential healthcare caused by social factors such as public health, education and income inequality.

The 5-year business plan establishes the "Access to Healthcare" policy of Daiichi Sankyo Group, which is the pillar for activities such as the "promotion of research and development," "improved access to pharmaceuticals," and "reinforcement of regional medical infrastructures," to be implemented mainly by the CSR Department Global Health Team. Initiatives for the Value Chain from research and development to manufacturing, sales and credibility assurance activities are being made as the Group. Initiatives for resolving these challenges contribute to the "Goal 3: Ensure healthy lives and promote wellbeing for all at all ages" of the Sustainable Development Goals (SDGs) established by the United Nations.



CSR Highlights	
Targets <ul style="list-style-type: none"> ▶ Addressing unmet healthcare needs ▶ Resolving access barriers to essential healthcare caused by social factors such as public health, education and income inequality 	Fiscal 2017 Accomplishments <ul style="list-style-type: none"> ▶ Establishing the Daiichi Sankyo Group's Access to Healthcare Policy ▶ Continued initiatives targeting rare diseases ▶ Kitasato Daiichi Sankyo Vaccine has received the "Vietnamese Minister of Health's Certificate of Good Performance Award"

How we address CSR issues

Materiality Approaches to global health

Participation in the Global Health Innovative Technology Fund

The Daiichi Sankyo Group has been funding the Global Health Innovative Technology (GHIT) Fund for its first phase, five years since its establishment in April 2013. Created to promote the development of drugs for combating infectious diseases in developing countries, the

GHIT Fund is a public-private partnership originating in Japan and supported by the government of Japan, six Japanese pharmaceutical companies, and the Bill & Melinda Gates Foundation. During this time, the Fund has contributed to the progress of many innovative product developments through its investments.

The Group is participating in joint development with the Fund by utilizing its compound library (consisting of small molecules and natural substances) in a screening program through the Fund to explore candidate compounds to treat malaria and neglected tropical diseases (NTDs), namely

leishmaniasis and Chagas disease. This program is at the lead-compound optimization stage for malaria and the lead-compound creation stage for leishmaniasis and Chagas disease.

The Group will continue to contribute to this Fund, which began its second phase in April 2018.

Continued initiatives targeting rare diseases

The Group has been expanding healthcare access to fight rare diseases as one of its initiatives toward resolving social issues related to health and medical care. We supply pharmaceuticals such as *Biopten*^{*1}, *Methylene Blue*^{*2}, and *Gabalon*^{*3} for rare diseases.

Daiichi Sankyo also provides *DS-5141* (treatment for Duchenne muscular dystrophy), which is being jointly developed with the Orphan Disease Treatment Institute^{*4}, and *G47Δ* (*DS-1647*: oncolytic virus), which is being jointly developed with Professor Tomoki Todo of the Institute of Medical Science of the University of Tokyo. Each treatment has been designated for the Sakigake Designation System^{*5}, and the *G47Δ* has been specified as an orphan regenerative medical product. In this way, we continue to strive to resolve issues related to rare diseases by applying our external resources such as joint development in addition to our in-house resources.

^{*1} Natural tetrahydrobiopterin agent
^{*2} Treatment for toxic methemoglobinemia
^{*3} An agent used for ITB treatment to suppress spasticity through direct administration of baclofen in the area of the spinal cord
^{*4} A joint investment company comprising Daiichi Sankyo and funds operated by the Innovation Network Corporation of Japan and Mitsubishi UFJ Capital Co., Ltd.
^{*5} A system to promote early clinical research/trials in Japan aiming at early practical application for innovative pharmaceuticals by conducting priority consultations, prior assessment, and priority reviews.

Healthcare services in Tanzania and China

We work together with NGO Plan International Japan to provide mobile healthcare field clinic services in Tanzania and to cultivate healthcare workers in China's Yunnan Province. Evaluation items have been set for these activities, and progress is continuously monitored (see page 90 "External Voice"). Additionally, these activities have received recognition as initiatives from Access Accelerated^{*}, and we have been reporting on activity results.

^{*} An initiative through which 24 pharmaceutical companies from Japan, the United States, and Europe work together with The World Bank Group and the Union for International Cancer Control to improve prevention, diagnosis, and treatment options for non-communicable diseases (NCDs) in low-income and lower-middle income countries.

Mobile Healthcare Field Clinic Services in Tanzania

In Tanzania, we have been operating mobile healthcare field clinics in cooperation with non-governmental organizations (NGOs), local governments, and local

communities since fiscal 2011 to contribute to regions where medical infrastructure, doctors, and transportation to hospitals are all insufficient. In line with the Goal 3 of the SDGs, we make efforts to improve the ratio of pregnant women who receive prenatal examinations as well as the ratio of children receiving vaccines in areas with healthcare access issues such as high infant and mother mortality rates. Daiichi Sankyo is also focusing on training community healthcare workers to support these activities.

Progress report on Mobile Healthcare Field Clinic Services in Tanzania (February 2017 to December 2017)

Number of mobile healthcare field clinics	521 times
Number of infants less than one year old who have received a triple vaccine	5,934
Number of pregnant women who received prenatal checkups (at 16 weeks)	2,782
Number of participants in the campaign to raise awareness	13,509
Number of individuals who received training for healthcare workers	110



A scene from the pregnant women who received prenatal checkups

Cultivation of Healthcare Workers in China

In July 2015, the Company commenced a project targeting approximately 60,000 households in six townships in Guangnan County in the Yunnan Province of China. Daiichi Sankyo is supporting activities in the aforementioned regions to cultivate healthcare workers capable of contributing to better healthcare for children and mothers and to provide healthcare education to local residents. The Company is focusing on improving the health and nutrition among children aged five and under in this impoverished area. Over the project's five-year period, we have been working to cultivate healthcare professionals through a series of Integrated Management of Childhood Illness (IMCI) strategy training sessions, while also establishing community center to offer education for improving the ability of local residents to address pediatric diseases.

Up to now, approximately 260 healthcare professionals (village doctors) have received IMCI training such as how to

Improving Access to Healthcare

treat diseases in children and infant care. Improved healthcare quality for local residents can be anticipated through the activities of these village doctors.

Progress report on training healthcare workers in Yunnan Province of China (January 2015 to December 2017)

Number of participants in IMCI training	257
Number of participants in IMCI refresher training	201
Number of participants in Essential Newborn Care* training	202
Number of participants in community center activities	9,923



A scene from the essential newborn care training

* Essential newborn care (ENC) is a set of guidelines recommended by the World Health Organization (WHO) on activities aimed at reducing infant mortality in developing countries where healthcare systems are limited. These activities incorporate the three main principles of ENC: moisturizing, nutrition (breastfeeding), and disease prevention.

Technical Cooperation for MR Vaccine Production

For five years until March 2018, Kitasato Daiichi Sankyo Vaccine cooperated with the Japan International Cooperation Agency (JICA) for the Vietnam POLYVAC* "MR Vaccine Production Technology Transfer Project." This technology transfer project has been incorporated into the MR vaccine expansion project with Vietnam-made vaccines, and administration of the vaccine for children in Vietnam started in March 2018. From now on, the country will be able to take swift action without relying on imported vaccines for measles or rubella outbreaks. The Company's contribution to this project has been highly regarded in Vietnam, and earned the Vietnamese Minister of Health's "Certificate of Good Performance Award" in September 2017, which is the most prestigious award for achievements in Vietnamese healthcare.

* Center for Research and Production of Vaccines and Biologicals in Vietnam



A scene from the awards ceremony of the Vietnamese Minister of Health's "Certificate of Good Performance Award"

The Company updates its corporate website with information on other initiatives.
https://www.daiichisankyo.com/about_us/responsibility/csr/business/medical/index.html

External Voice

We will promote innovative activities through partnership with corporates and private sector

The provision of mobile healthcare field clinics in Tanzania in collaboration with Daiichi Sankyo and the cultivation of healthcare workers in China are activities contributing to the accomplishment of Goal 3 of the Sustainable Development Goals (SDGs).

In addition to the outputs and outcome, a recent activity evaluation requires us to produce a social impact from a mid-to-long-term perspective. In Tanzania, a local community has built a simple facility for prenatal checkups for pregnant women and educational activities for local people in liaison with our activities proactively even without help from district government or NGOs. We consider this behavioral change in local people as one of social impacts. We will continue to support these community members so that they can solve local issues on their own in the future.



A simple facility built by the community



Ikuro Sato

Deputy National Director, General Manager, Plan International Japan



Social Contribution Activities

We will not only contribute to society through our business activities but also voluntarily seek to help resolve the various issues that we face in ensuring the sound development of society.

Basic Policy

The Daiichi Sankyo Group has established the Basic Group Social Contribution Policy, which guides various initiatives that contribute to the advancement of medicine and pharmacology, and society as a whole. We perceive social contribution activities as "social investments" when proceeding with our activities, actively highlighting social issues that need attention and conducting social contribution activities with our own corporate resources. The Group also focuses on cooperation and collaboration with organizations such as NPOs and NGOs to reinforce activities that aim to resolve social issues. Furthermore, we create opportunities and implement environmental improvements that allow employees to actively participate in social activities such as providing volunteer vacations.

Basic Group Social Contribution Policy

- We will help create a sustainable society by engaging in activities that contribute to society.
- We will especially prioritize progress in medicine and pharmacology, social welfare, and environmental conservation. We will assist with disaster restoration, youth education, and promote culture and arts.
- We will foster healthy social development by participating in and supporting voluntary activities.
- We will engage with and prosper with communities.

CSR Highlights

Targets

- ▶ Promote activities based on global and regional needs
- ▶ Reconstruction support following the Great East Japan Earthquake

Fiscal 2017 Accomplishments

- ▶ Held the "Daiichi Sankyo Presents Family Tie Theater" program
- ▶ Supported overseas forest restoration projects, which are long-term reconstruction assistance measures for the Great East Japan Earthquake

How we address CSR issues

Support for Cancer Patients and their Families

Daiichi Sankyo has been holding the "Daiichi Sankyo Presents Family Tie Theater" program in cooperation with the Shiki Theatre Company and NPO Cancer Support Community Japan every year since fiscal 2010. In fiscal 2017, approximately 400 patients and their families were invited to the event, and eight employees from the Group participated as volunteers for it.



The employee volunteers managed overall operations including reception and visitor guidance

Reconstruction Support Following the Great East Japan Earthquake

Daiichi Sankyo affirms the purpose of OISCA's Coastal Forest Restoration Project, a long-term post-Great East Japan Earthquake reconstruction support program conducted by Natori City in Miyagi Prefecture, and has been supporting this initiative since 2012. In fiscal 2017, 24 volunteers from the Group participated in tree-raising activities.



Participating employee volunteers

The Company updates its corporate website with information on other initiatives.
https://www.daiichisankyo.com/about_us/responsibility/philanthropy/index.html